0001104659-23-082729.txt : 20230720 0001104659-23-082729.hdr.sgml : 20230720 20230720161752 ACCESSION NUMBER: 0001104659-23-082729 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230718 FILED AS OF DATE: 20230720 DATE AS OF CHANGE: 20230720 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Parsey Merdad CENTRAL INDEX KEY: 0001792150 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41742 FILM NUMBER: 231099917 MAIL ADDRESS: STREET 1: 333 LAKESIDE DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sagimet Biosciences Inc. CENTRAL INDEX KEY: 0001400118 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205991472 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 155 BOVET RD., SUITE 303 CITY: SAN MATEO STATE: CA ZIP: 94402 BUSINESS PHONE: (650) 561-8600 MAIL ADDRESS: STREET 1: 155 BOVET RD., SUITE 303 CITY: SAN MATEO STATE: CA ZIP: 94402 FORMER COMPANY: FORMER CONFORMED NAME: 3-V Biosciences, Inc. DATE OF NAME CHANGE: 20070521 4 1 tm2321276-18_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-07-18 0 0001400118 Sagimet Biosciences Inc. SGMT 0001792150 Parsey Merdad SAGIMET BIOSCIENCES INC. 155 BOVET RD., SUITE 303 SAN MATEO CA 94402 1 0 0 0 0 Common Stock 2023-07-18 4 D 0 8677 D 0 D Series A Common Stock 2023-07-18 4 A 0 8677 A 8677 D Series A Common Stock 2023-07-18 4 C 0 4117 A 12794 D Series E Preferred Stock 2023-07-18 4 C 0 327309 0 D Series A Common Stock 4117 0 D Stock Option (Right to Buy) 11.13 2023-07-18 4 D 0 2086 0 D 2024-03-12 Common Stock 2086 0 D Stock Option (Right to Buy) 11.13 2023-07-18 4 A 0 2086 0 A 2024-03-12 Series A Common Stock 2086 2086 D Stock Option (Right to Buy) 23.05 2023-07-18 4 D 0 3349 0 D 2024-12-16 Common Stock 3349 0 D Stock Option (Right to Buy) 23.05 2023-07-18 4 A 0 3349 0 A 2024-12-16 Series A Common Stock 3349 3349 D Stock Option (Right to Buy) 23.05 2023-07-18 4 D 0 144 0 D 2025-02-05 Common Stock 144 0 D Stock Option (Right to Buy) 23.05 2023-07-18 4 A 0 144 0 A 2025-02-05 Series A Common Stock 144 144 D Stock Option (Right to Buy) 6.36 2023-07-18 4 D 0 23216 0 D 2029-04-27 Common Stock 23216 0 D Stock Option (Right to Buy) 6.36 2023-07-18 4 A 0 23216 0 A 2029-04-27 Series A Common Stock 23216 23216 D Stock Option (Right to Buy) 6.36 2023-07-18 4 D 0 23839 0 D 2031-01-26 Common Stock 23839 0 D Stock Option (Right to Buy) 6.36 2023-07-18 4 A 0 23839 0 A 2031-01-26 Series A Common Stock 23839 23839 D Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Series E Preferred Stock had no expiration date. The shares underlying this option are fully vested and exercisable as of the date hereof. /s/ Dennis Hom, Attorney-in-Fact 2023-07-20